Do neurologists agree in diagnosing drug resistance in adults with focal epilepsy?
- PMID: 30585315
- PMCID: PMC7379205
- DOI: 10.1111/epi.14622
Do neurologists agree in diagnosing drug resistance in adults with focal epilepsy?
Abstract
Objective: To evaluate interrater agreement in categorizing treatment outcomes and drug responsiveness status according to the International League Against Epilepsy (ILAE) definition of drug-resistant epilepsy.
Methods: A total of 1053 adults with focal epilepsy considered by the investigators to meet ILAE criteria for drug resistance were enrolled consecutively at 43 centers and followed up prospectively for 18-34 months. Treatment outcomes for all antiepileptic drugs (AEDs) used up to enrollment (retrospective assessment), and on an AED newly introduced at enrollment, were categorized by individual investigators and by 2 rotating members of a 16-member expert panel (EP) that reviewed the patient records independently. Interrater agreement was tested by Cohen's kappa (k) statistics and rated according to Landis and Koch's criteria.
Results: Agreement between EP members in categorizing outcomes on the newly introduced AED was almost perfect (90.1%, k = 0.84, 95% confidence interval [CI] 0.80-0.87), whereas agreement between the EP and individual investigators was moderate (70.4%, k = 0.57, 95% CI 0.53-0.61). Similarly, categorization of outcomes on previously used AEDs was almost perfect between EP members (91.7%, k = 0.83, 95% CI 0.81-0.84) and moderate between the EP and investigators (68.2%, k = 0.50, 95% CI 0.48-0.52). Disagreement was related predominantly to outcomes considered to be treatment failures by the investigators but categorized as undetermined by the EP. Overall, 19% of patients classified as having drug-resistant epilepsy by the investigators were considered by the EP to have "undefined responsiveness."
Significance: Interrater agreement in categorizing treatment outcomes according to ILAE criteria ranges from moderate to almost perfect. Nearly 1 in 5 patients considered by enrolling neurologists to be "drug-resistant" were classified by the EP as having "undefined responsiveness."
Keywords: ILAE definition; antiepileptic drugs; classification; drug-resistant epilepsy; epilepsy; reliability.
© 2018 The Authors. Epilepsia published by Wiley Periodicals, Inc. on behalf of International League Against Epilepsy.
Figures
Comment in
-
Commentary on "Do neurologists agree in diagnosing drug resistance in adults with focal epilepsy?".Epilepsia. 2019 Jun;60(6):1124-1125. doi: 10.1111/epi.14886. Epub 2019 May 9. Epilepsia. 2019. PMID: 31071233 No abstract available.
References
-
- Perucca E. Pharmacoresistance in epilepsy. How should it be defined? CNS Drugs. 1998;10:171–9.
-
- Téllez‐Zenteno JF, Hernández‐Ronquillo L, Buckley S, et al. A validation of the new definition of drug‐resistant epilepsy by the International League Against Epilepsy. Epilepsia. 2014;55:829–34. - PubMed
-
- Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51:1069–77. - PubMed
-
- Kwan P, Brodie MJ. Definition of refractory epilepsy: defining the indefinable? Lancet Neurol. 2010;9:27–9. - PubMed
-
- Wiebe S. Definition of drug‐resistant epilepsy: is it evidence based? Epilepsia. 2013;54(Suppl 2):9–12. - PubMed
